ARTICLE | Company News
Valeant slides on psoriasis delay
June 18, 2018 9:38 PM UTC
Ortho Dermatologics said it received a complete response letter from FDA to an NDA for Duobrii (IDP-118) to treat plaque psoriasis. Ortho parent Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) slid $3.32 (12%) to $23.54 on NYSE and C$4.38 (12%) to C$31.09 in Toronto on Monday.
According to Valeant, FDA had questions related to pharmacokinetic data. ...
BCIQ Company Profiles